kidney cancer

ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
Fierce Pharma
ASCO 2023
Merck
Keytruda
EGFR lung cancer
Roche
Tecentriq
kidney cancer
Flag link:
HistoSonics’ Kidney Cancer Trial Using Non-Invasive Histotripsy Gets FDA Nod
HistoSonics’ Kidney Cancer Trial Using Non-Invasive Histotripsy Gets FDA Nod
Xtalks
HistoSonics
FDA
devices
Medtech
histotripsy
kidney cancer
clinical trials
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Flag link:
Bristol Myers scraps $2B Nektar partnership after trial failures
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
Flag link:
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
Fierce Pharma
Bristol Myers Squibb
Opdivo
Yervoy
kidney cancer
ESMO
Flag link:
FDA starts speedy review of Keytruda for adjuvant kidney cancer
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Pharmaforum
Merck
FDA
Keytruda
kidney cancer
Flag link:
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
EP Vantage
FDA
Axsome Therapeutics
Sanofi
Merck
Pompe disease
depression
kidney cancer
Keytruda
Flag link:
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
Fierce Pharma
ASCO 2021
Merck
Keytruda
kidney cancer
Sutent
Pfizer
Flag link:
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Flag link:
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
Flag link:
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
Pharmaforum
Bristol-Myers Squibb
Opdivo
kidney cancer
Flag link:
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Flag link:
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
2 Biotechs Battling Against Kidney Cancer
2 Biotechs Battling Against Kidney Cancer
Motley Fool
kidney cancer
Nektar
Exelixis
Flag link:
Renal Cell Carcinoma Space in Focus: Some Key Developments
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Flag link:
Keytruda combo cleared as first-line kidney cancer treatment in EU
Keytruda combo cleared as first-line kidney cancer treatment in EU
Pharmaforum
Merck
Keytruda
kidney cancer
Europe
Flag link:
Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII
Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII
Endpoints
Immunicum
immune priming
metastatic kidney cancer
kidney cancer
clinical trials
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:

Pages